PanGen Biotech Balance Sheet Health
Financial Health criteria checks 6/6
PanGen Biotech has a total shareholder equity of ₩14.8B and total debt of ₩1.7B, which brings its debt-to-equity ratio to 11.7%. Its total assets and total liabilities are ₩22.6B and ₩7.8B respectively.
Key information
11.7%
Debt to equity ratio
₩1.73b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩425.45m |
| Equity | ₩14.80b |
| Total liabilities | ₩7.85b |
| Total assets | ₩22.64b |
Financial Position Analysis
Short Term Liabilities: A222110's short term assets (₩10.0B) exceed its short term liabilities (₩5.7B).
Long Term Liabilities: A222110's short term assets (₩10.0B) exceed its long term liabilities (₩2.1B).
Debt to Equity History and Analysis
Debt Level: A222110's net debt to equity ratio (8.8%) is considered satisfactory.
Reducing Debt: A222110's debt to equity ratio has reduced from 53% to 11.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A222110 has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A222110 is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.